Literature DB >> 16416732

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.

Raffit Hassan1, Zoltan G Laszik, Megan Lerner, Mark Raffeld, Russell Postier, Daniel Brackett.   

Abstract

Mesothelin, a cell surface glycoprotein present on normal mesothelial cells, has been reported to be expressed in pancreatic adenocarcinomas. We conducted this study to fully characterize mesothelin expression in surgically resected, formalin-fixed, paraffin-embedded tissue specimens of 18 pancreatic adenocarcinomas, 9 adenocarcinomas of the ampulla of Vater, 12 adenocarcinomas of the common bile duct, and 17 cases of chronic pancreatitis. Mesothelin immunostaining was performed using the antimesothelin monoclonal antibody 5B2. All 18 cases (100%) of pancreatic adenocarcinomas showed mesothelin expression, as did 8 (89%) of 9 cases of ampullar adenocarcinoma and all 12 cases (100%) of common bile duct adenocarcinoma. In all cases of pancreaticobiliary adenocarcinoma, the adjacent normal pancreas did not stain for mesothelin. Of 17 specimens of chronic pancreatitis, 16 were negative for mesothelin expression, and 1 case showed weak mesothelin staining of fewer than 5% of normal pancreatic ducts. Our results demonstrated mesothelin expression in the majority of pancreaticobiliary adenocarcinomas and no expression in normal pancreatic tissues and in chronic pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16416732

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  103 in total

1.  Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.

Authors:  Elad Sharon; Jingli Zhang; Kevin Hollevoet; Seth M Steinberg; Ira Pastan; Masanori Onda; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Raffit Hassan
Journal:  Clin Chem Lab Med       Date:  2012-04       Impact factor: 3.694

2.  A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Authors:  Dung T Le; Dirk G Brockstedt; Ran Nir-Paz; Johannes Hampl; Shruti Mathur; John Nemunaitis; Daniel H Sterman; Raffit Hassan; Eric Lutz; Bentley Moyer; Martin Giedlin; Jana-Lynn Louis; Elizabeth A Sugar; Alice Pons; Andrea L Cox; Jordana Levine; Aimee Luck Murphy; Peter Illei; Thomas W Dubensky; Joseph E Eiden; Elizabeth M Jaffee; Daniel A Laheru
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

3.  Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis.

Authors:  Qianqian Wang; Tao Wang; Zhu Wang; Hong Zheng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Authors:  Raffit Hassan; Steven J Cohen; Martin Phillips; Ira Pastan; Elad Sharon; Ronan J Kelly; Charles Schweizer; Susan Weil; Daniel Laheru
Journal:  Clin Cancer Res       Date:  2010-10-29       Impact factor: 12.531

5.  Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.

Authors:  Tapan K Bera; Wenlong Liu; Jasmin Leshem; Emily King; Serguei Kozlov; Ira Pastan
Journal:  J Immunother       Date:  2019-05       Impact factor: 4.456

Review 6.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

7.  Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.

Authors:  Yuan Chen; Shao-An Xue; Shahriar Behboudi; Goran H Mohammad; Stephen P Pereira; Emma C Morris
Journal:  Clin Cancer Res       Date:  2017-07-14       Impact factor: 12.531

8.  Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

Authors:  Hector Alvarez; Pamela Leal Rojas; Ken-Tye Yong; Hong Ding; Gaixia Xu; Paras N Prasad; Jean Wang; Marcia Canto; James R Eshleman; Elizabeth A Montgomery; Anirban Maitra
Journal:  Nanomedicine       Date:  2008-08-08       Impact factor: 5.307

9.  Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.

Authors:  Sabrina C Sopha; Purva Gopal; Nipun B Merchant; Frank L Revetta; David V Gold; Kay Washington; Chanjuan Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

10.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.